# US 2005/0239871 A1 · Statins for the treatment of ocular hypertension and glaucoma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0239871 A1
- Document ID: US20050239871A1
- Status: Published application
- Kind: A1
- Application number: 11/114,512
- Filed: 2005-04-25
- Published: 2005-10-27
- Earliest claimed: 2004-04-26
- Assignees: Alcon Inc.
- Inventors: Mark Hellberg; Debra Fleenor; Allan Shepard; Iok-Hou Pang
- Web page: https://patentgrep.com/patent/US20050239871A1

## CPC

- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/225: Polycarboxylic acids
- A61K 31/366: having six-membered rings, e.g. delta-lactones
- A61K 31/401: Proline; Derivatives thereof, e.g. captopril
- A61P 27/00: Drugs for disorders of the senses
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The use of HMG-CoA reductase inhibitors (e.g., statins) to treat glaucoma, control intraocular pressure, preserve the trabecular meshwork, protect against ocular neurodegeneration and/or protect against glaucomatous retinopathy is described. The preferred HMG-CoA reductase inhibitors, which are statins having an RI value of 0.2 to 0.7 (e.g., pravastatin), are administered via topical application to the affected eye(s) of the patient.

## Claims

### Claim 1

A method for the treatment of glaucoma in a patient which comprises administering a pharmaceutically effective amount of a composition comprising at least one HMG-CoA reductase inhibitor to said patient.

### Claim 2 (depends on 1)

The method of claim 1, wherein said HMG-CoA reductase inhibitor is at least one statin.

### Claim 3 (depends on 2)

The method of claim 2, wherein said at least one statin comprises compactin, lovastatin, simvastatin, pravastatin, mevastatin, fluvastatin, rosuvastatin, atorvastatin, pitavastatin. cervistatin, berivastatin, dalvastatin, glenvastatin, a prodrug thereof, or a derivative thereof, or a combination thereof.

### Claim 4 (depends on 2)

The method of claim 2, wherein said at least one statin has an RI value of 0.2 to 0.7 and said composition is administered topically to at least one eye of said patient.

### Claim 5 (depends on 1)

The method of claim 1, wherein said HMG-CoA reductase inhibitor has the formula A-B, wherein:
R1=CO2R, CONR5R6 or CH2OR7, or R1 and R3 form a lactone;
R=H or a cationic salt moiety, or CO2R forms a pharmaceutically acceptable ester moiety;
R2, R3, R4=same or different=H, C(O)R8 or C(O)NR5R6;
R5, R6=same or different=H or alkyl;
R7=H or C(O)R8; and
R8=alkyl.

### Claim 6 (depends on 1)

The method of claim 1, wherein said HMG-CoA reductase inhibitor is a HMG-CoA reductase inhibitor including one of the structures of B:
wherein:
R1=CO2R, CONR5R6 or CH2OR7, or R1 and R3 together form a lactone;
R=H or a cationic salt moiety, or CO2R forms a pharmaceutically acceptable ester moiety;
R2, R3, same or different H, C(O)R8 or C(O)NR5R6;
R5, R6=same or different=H or alkyl;
R7=H or C(O)R8; and
R8=alkyl.

### Claim 7 (depends on 1)

The method of claim 1, wherein said composition is administered topically to at least one eye of said patient.

### Claim 8 (depends on 1)

The method of claim 1, wherein said HMG-CoA reductase inhibitor comprises from about 0.05% to about 2.0% by weight of said composition.

### Claim 9

A method of controlling normal or elevated intraocular pressure in a patient which comprises administering a pharmaceutically effective amount of a composition comprising at least one HMG-CoA reductase inhibitor to said patient.

### Claim 10 (depends on 9)

The method of claim 9, wherein said HMG-CoA reductase inhibitor is at least one statin.

### Claim 11 (depends on 10)

The method of claim 10, wherein said at least one statin comprises compactin, lovastatin, simvastatin, pravastatin, mevastatin, fluvastatin, rosuvastatin, atorvastatin, pitavastatin. cervistatin, berivastatin, dalvastatin, glenvastatin, a prodrug thereof, or derivative thereof, or analog thereof, or a combination thereof.

### Claim 12 (depends on 10)

The method of claim 10, wherein said at least one statin has an RI value of 0.2 to 0.7 and said composition is administered topically to at least one eye of said patient.

### Claim 13 (depends on 9)

The method of claim 9, wherein said HMG-CoA reductase inhibitor is:
R1=CO2R, CONR5R6 or CH2OR, or R1 and R3 forms a lactone;
R=H or a cationic salt moiety, or CO2R forms a pharmaceutically acceptable ester moiety;
R2, R3, R4=same or different=H, C(O)R8 or C(O)NR5R6;
R5, R6=same or different=H or alkyl;
R7=H or C(O)R8; and
R8=alkyl.

### Claim 14 (depends on 9)

The method of claim 9, wherein said composition is administered topically to at least one eye of said patient.

### Claim 15 (depends on 9)

The method of claim 9, wherein said HMG-CoA reductase inhibitor comprises from about 0.05% to about 2% by weight of said composition.

### Claim 16

A method to preserve the trabecular meshwork of a patient which comprises administering a pharmaceutically effective amount of a composition comprising at least one HMG-CoA reductase inhibitor to said patient.

### Claim 17 (depends on 16)

The method of claim 16, wherein HMG-CoA reductase inhibitor is at least one statin.

### Claim 18

A method to protect against ocular neurodegeneration which comprises administering a pharmaceutically effective amount of a composition comprising at least one HMG-CoA reductase inhibitor to said patient.

### Claim 19 (depends on 18)

The method of claim 18, wherein said HMG-CoA reductase inhibitor is at least one statin having an RI value of 0.2 to 0.7 and said composition is topically administered to at least one eye of said patient.

### Claim 20

A method to protect against glaucomatous retinopathy of a patient which comprises administering a pharmaceutically effective amount of a composition comprising at least one HMG-CoA reductase inhibitor to said patient.

### Claim 21 (depends on 20)

The method of claim 20, wherein said HMG-CoA reductase inhibitor is at least one statin having an RI value of 0.2 to 0.7 and said composition is topically administered to at least one eye of said patient.

### Claim 22 (depends on 20)

The method of claim 20, wherein said composition is administered intraocularly to at least one eye of said patient.

### Claim 23 (depends on 1)

The method of claim 1, further comprising administering, either as part of said composition or as a separate administration, a β-blocker, a carbonic anhydrase inhibitor, an α1 antagonist, an α2 agonist, a miotic, a prostaglandin analog, a neuroprotectant, or any combination thereof.

### Claim 24 (depends on 1)

The method of claim 1, further comprising administering, either as part of said composition or as a separate administration, at least one carbonic anhydrase inhibitor.

### Claim 25 (depends on 9)

The method of claim 9, further comprising administering, either as part of said composition or as a separate administration, a β-blocker, a carbonic anhydrase inhibitor, an α1 antagonist, an α2 agonist, a miotic, a prostaglandin analog, a neuroprotectant, or any combination thereof.

### Claim 26 (depends on 9)

The method of claim 9, further comprising administering, either as part of said composition or as a separate administration, at least one carbonic anhydrase inhibitor.

### Claim 27 (depends on 18)

The method of claim 18, further comprising administering, either as part of said composition or as a separate administration, β-blocker, a carbonic anhydrase inhibitor, an α1 antagonist, an α2 agonist, a miotic, a prostaglandin analog, a neuroprotectant, or any combination thereof.

### Claim 28 (depends on 18)

The method of claim 18, further comprising administering, either as part of said composition or as a separate administration, at least one carbonic anhydrase inhibitor.
